Plus Therapeutics (PSTV)
Develops targeted radiotherapeutics and CNSide diagnostics for central nervous system cancers.
Something off on this page? Send us feedback.
Plus Therapeutics is a Houston-based clinical-stage company developing targeted radiopharmaceuticals and precision diagnostics for brain and other central nervous system cancers. Its lead program, REYOBIQ, is being studied in recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancer, while CNSide supports detection and characterization of tumor cells in cerebrospinal fluid.
Plus Therapeutics develops medicines and diagnostics for cancers that affect the brain, spinal cord, and cerebrospinal fluid. The company's lead drug candidate, REYOBIQ, uses rhenium-186 inside a nanoliposome carrier to deliver localized beta radiation that can be imaged during administration. Its clinical work is focused on recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancer, with delivery through convection-enhanced catheters or an Ommaya reservoir depending on the disease setting.
Through CNSide Diagnostics, Plus also offers laboratory-developed cerebrospinal fluid assays intended to detect, quantify, and characterize tumor cells in patients whose cancers have spread to the central nervous system. The business remains dependent on clinical trial execution, manufacturing scale-up, regulatory review, reimbursement for diagnostics, and access to additional capital.
Company facts
Target rangeAs of Aug 27, 2026
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Mar 31, 2026 | D. Boral Capital | Downgrade | Buy | Hold | ||
| Jan 23, 2026 | H.C. Wainwright | Target | $2 | $1 | ||
| Nov 26, 2025 | H.C. Wainwright | Target | $2 | |||
| Sep 3, 2025 | D. Boral Capital | Upgrade | Hold | Buy | ||
| May 5, 2025 | D. Boral Capital | Downgrade | Buy | Hold |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $8.6M · Total debt $44.0K · Total assets $14.0M · Shareholders' equity $5.5M
- Revenue
- $411.0K
- Operating income
- −$9.1M
- Net income
- −$9.0M
No dividends on record.
| Institutions22 holders · as of Jun 30, 2026 | ≥ 8.30% | 630.1K shares | |
| Insiders9 holders · as of Jul 1, 2026 | 0.90% | 68.2K shares | |
| Strategic holders1 holder · as of Aug 28, 2018 | 0.00% | 20 shares | |
| Otherremainder | ≤ 90.80% | 6.89M shares |
7.59M company shares as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (7.59M in the company's Sep 3, 2026 report, 2.42M elsewhere); stakes use the report.
Institutional filings for CNSY (100% of the company) are not on file here, so the institutional figure is a floor.
A stock split fell inside the quarter, so quarter-on-quarter changes are not shown.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Vanguard Capital Management LLCInstitution | 4.02% | 304,745 | 13Fas of Jun 30, 2026 |
BlackRock, Inc.Institution | 1.26% | 95,983 | 13Fas of Jun 30, 2026 |
Geode Capital Management, LLCInstitution | 1.00% | 76,155 | 13Fas of Jun 30, 2026 |
Marc H. HedrickInsiderdirector, officer: Chief Executive Officer | 0.59% | 44,483 | Form 4filed Jul 1, 2026 ↗ |
Vanguard Fiduciary Trust CoInstitution | 0.49% | 36,868 | 13Fas of Jun 30, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Nov 4, 2025 | Andrew John Hugh MacIntyre Sims | officer: Chief Financial Officer | +20,000 | $0.5100 |
Not reported.